PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26026F0282Winrevair 45mg VIAL INJ LYPHL — Merck Sharp & Dohme LLC

Merck Sharp & Dohme LLC holds $7.7B across 101 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 1 related award under parent 36F79725D0146. The prior award was single-bid — competitive dynamics may favor a challenge. Recompete timing centers on the May 31, 2027 PoP end — agencies typically plan 12–18 months ahead.

260-Network Contract Office 20 (36C260)

Awarding office

Merck Sharp & Dohme LLC

Recipient

May 31, 2027

PoP end

$342K

Obligated

$342K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Merck Sharp & Dohme LLC — $90

Contract facts

Federal

Contract number36C26026F0282

Also listed as36C260-26-F-0282

Also listed as36F79725D0146-36C26026F0282

Agency260-Network Contract Office 20 (36C260)

Awarding office260-Network Contract Office 20 (36C260)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentMerck Sharp & Dohme LLC

CAGE6B2S4

UEIFCFDA78HKKG2

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79725D0146

Place of performanceMEMPHIS TN

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startJun 1, 2026

PoP end (current)May 31, 2027

Obligated$342K

Current value$342K

Potential value$342K

WINREVAIR 45MG/VIAL INJ,LYPHL is a federal award for 260-Network Contract Office 20 (36C260) held by Merck Sharp & Dohme LLC. Estimated value $342K ($342K obligated). Current period of performance ends May 31, 2027. Last award drew 1 bidder. Place of performance: MEMPHIS TN.

Recompete timing

Public

● Expiring in 283 days

Current PoP ends May 31, 2027 (283 days remaining). Agencies typically plan 12–18 months ahead — at 9.3 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Merck Sharp & Dohme LLC — $7.7B obligated across 101 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($7.7B) · all agencies

Department of Health and Human Services (HHS)$7.7B · 100%Department of Veterans Affairs (VA)$2.3M · 0%Department of Justice (DOJ)$98K · 0%

Open full company profile →

Related awards

Same parent · incumbent

HHSO100201700012C

MERCK - EBOLA ZAIRE VACCINE UPDATE SECTION J

$236.3M

Sep 27, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26026F0282?

36C26026F0282 (Winrevair 45mg VIAL INJ LYPHL) is a 260-Network Contract Office 20 (36C260) award with a potential value of $342K, currently held by Merck Sharp & Dohme LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C260-26-F-0282?

36C260-26-F-0282 is the dashed form of PIID 36C26026F0282 (Winrevair 45mg VIAL INJ LYPHL), held by Merck Sharp & Dohme LLC. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26026F0282?

260-Network Contract Office 20 (36C260) awarded 36C26026F0282 to Merck Sharp & Dohme LLC (potential $342K).

Who is the incumbent on 36C26026F0282?

Merck Sharp & Dohme LLC is the incumbent with $7.7B across 101 related awards in SCOUT’s public footprint. The current period of performance ends May 31, 2027.

When does Merck Sharp & Dohme LLC’s 36C26026F0282 come up for recompete?

SCOUT tracks a period-of-performance end of May 31, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action May 11, 2026